Skip to main content
Signal8
Launch Terminal

RetinalGenix Technologies Inc. (RTGN)

RetinalGenix Technologies Inc. is a company dedicated to research and development within the field of ophthalmology. Its core mission involves devising advanced technologies aimed at detecting, supervising, identifying, and treating a range of visual conditions, including those affecting the eyes and those that could lead to vision loss. Their product lineup features the RetinalGeniX Imaging System, an apparatus for broad-scale retinal imaging and screening that does not require pupil dilation, particularly useful for diabetic patients. Additionally, they offer the RetinalCam, a device designed for real-time retinal monitoring and imaging in a home setting, which includes an alert function for medical practitioners. The company was founded in 2017, with its principal offices located in Petaluma, California. RetinalGenix Technologies Inc. operates as a subsidiary of Sanovas Ophthalmology, LLC.

Sector: Surgical & Medical Instruments & Apparatus

Industry: Medical - Devices

RetinalGenix Technologies Inc. logo

RetinalGenix Technologies Inc.

OTC:RTGNHealthcare
Mkt Cap-
Float6.25M
O/S-
Inst Own-
SI<0.1%
Dilution
RetinalGenix Technologies Inc. logoOTC:RTGN
FormDescription
10-Q
Quarterly Report
7
8-K
4.01,9.01
3
144
Notice of Proposed Sale of Securities
10-Q
Quarterly Report
6
NT 10-Q
SEC Filing
2
10-K
Annual Report
NT 10-K
SEC Filing
8-K
5.02
144
Notice of Proposed Sale of Securities
10-Q
Quarterly Report
144
Notice of Proposed Sale of Securities
10-Q/A
Quarterly Report (Amended)
10-Q
Quarterly Report
NT 10-Q
SEC Filing
144
Notice of Proposed Sale of Securities
EFFECT
Notice of Effectiveness
EFFECT
Notice of Effectiveness
POS AM
Post-Effective Amendment
POS AM
Post-Effective Amendment
POS AM
Post-Effective Amendment
POS AM
Post-Effective Amendment
144
Notice of Proposed Sale of Securities
10-Q
Quarterly Report
10-K
Annual Report
8-K
1.01,9.01

1-25 of 114